High Growth Tech Stocks To Explore This November 2024

In This Article:

As global markets navigate the uncertainties of the incoming Trump administration and fluctuating economic indicators, investors are closely watching the impact on key indices like the S&P 500 and Nasdaq Composite, which have seen significant changes in recent weeks. In this dynamic environment, identifying high-growth tech stocks requires a focus on companies with robust innovation capabilities and resilience to policy shifts that could affect their growth trajectories.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Yggdrazil Group

24.66%

85.53%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Seojin SystemLtd

33.54%

52.43%

★★★★★★

Medley

25.57%

31.67%

★★★★★★

Pharma Mar

26.94%

56.39%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Elliptic Laboratories

65.73%

103.55%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1297 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Seegene

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Seegene, Inc. is a global manufacturer and seller of molecular diagnostics products with a market cap of ₩1.01 trillion.

Operations: Seegene, Inc. generates revenue through the global sale of its molecular diagnostics products.

Seegene's recent strategic alliances and product developments underscore its innovative edge in the high-tech diagnostics field. The company has turned a corner financially, transitioning from a net loss to reporting substantial gains with a net income of KRW 23.64 billion over nine months, up from a previous loss, reflecting a significant recovery and growth trajectory. This resurgence is mirrored in their R&D commitment, where they've increased expenditure to further refine their real-time PCR technology—a move that not only enhances their product suite but also positions them well within the biotech sector's evolving demands. Moreover, Seegene's partnership with Werfen aims to expand its footprint in Europe’s IVD market through the newly formed Werfen-Seegene entity in Spain, expected to be operational by mid-2025. This strategic move could potentially amplify Seegene’s market share and bolster its global presence by leveraging local expertise and infrastructure to meet specific regional health challenges.

KOSDAQ:A096530 Revenue and Expenses Breakdown as at Nov 2024
KOSDAQ:A096530 Revenue and Expenses Breakdown as at Nov 2024

Intellect Design Arena

Simply Wall St Growth Rating: ★★★★☆☆